🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🫁 Summary of immunotherapies early stage NSCLC 1/3 ⭐️ Key clinical data as of June 2025 ※ #ASCO25 data included.

Sustained benefits of rux+pelabresib over rux+placebo in 1L MF at week 72 in the phase 3 MANIFEST2 study. Especially good to see the difference between the arms in rates of leukemic transformation narrowing over time. #EHA25 #MPNSM

These are important data and should change practice for LGL leukemia. Oncology Brothers

What patients are eligible for adjuvant CDK4/6i? We looked at this in ConcertAI: the approval of ribo doubled the pts eligible for adjuvant CDK4/6i (15%➡️30%) and provided an option for 10% of pts with N0 disease, those with the most aggressive cancers. esmoopen.com/article/S2059-…

Practical HCC treatment algorithm guiding choices from early-stage to systemic disease. More than a flowchart. OncoAlert Oncology Brothers

Daniel Shoskes MD, FRCS(C) Uromigos Ashish M. Kamat, MD, MBBS Tom Powles Sam S. Chang MD, MBA Mark Tyson Stephen Boorjian, MD DrBagrodia Stacy Loeb, MD Alexander Kutikov MD Angie Smith Sia Daneshmand, M.D. Petros Grivas Laura Bukavina Andrea Necchi Matt Galsky Benjamin Pradere IBCG Max Kates Thank you for catching my error, Daniel Shoskes MD, FRCS(C). Agree that an important part of interpreting "CR" is induction vs induction and re-induction. Below is the revised table.

ADCs are rapidly improving the way we treat every type of cancer. Their potential has been largely unleashed over the past 6 years— yet their technology is the result of a 100-year long, epic journey. Join Raffaele Colombo & me to uncover 10 milestones in the development of ADCs (🧵):

🔥 Breakthrough in extensive-stage small-cell lung cancer maintenance! 🫁Lurbinectedin + Atezolizumab doubled PFS vs Atezolizumab alone! 🫁OS benefit also significant (13.2 vs 10.6 mo) 💥 First phase 3 trial to improve both PFS & OS in 1L maintenance for ES-SCLC. OncoAlert

Key Myeloma therapy update for 2025 1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd). 2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use.

Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. news.abbvie.com/2025-06-16-Abb…

Imatinib the wonder drug Chronic eosinophilic leukemia. PDGFR breakpoint. Started Imatinib 400 mg Mon& fri 1 year out. Eosinophils down from 20k to 200. Spleen gone on imaging and exam. FISH now negative 𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM Oncology Brothers Aaron Goodman - “Papa Heme” Santhosh Ambika

After a few #ASCO25 updates, we are back this week with a re-do for Ovarian CA (last recorded in 2022) One 🆕 update is the approval of Mirvetuximab Sorvtansine (MIRV) for platinum-refractory ovarian CA. What target is needed for use of MIRV? Hem-Onc Fellows Network

Consensus definitions of high-risk smoldering and active Waldenstrom's per the latest IWWM-12 publication: pubmed.ncbi.nlm.nih.gov/40441983/ #lymsm

New in ESMO GI Onc- Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab. Dr. Marwan G. Fakih et al 📄 Practical guidance for managing key AEs with Lonsurf+Bevacizumab. 🩸 Neutropenia 💢 Hypertension 💊

Nice slides to show comparison of ARPIs available. Do u use low dose Abiraterone with food ? I do. Also repeat after me ARPI dose not work after ARPI . OncoAlert Yakup Ergün Yüksel Ürün Oncology Brothers

Excited to have our official X handle- ASCO EO/AYA Community of Practice Looking forward to connecting with the community here on X. Please consider joining our thriving CoP. Nikita Baclig Dr. Alique Topalian Allison Rosen, MS

After our daughter Ceci died at 15 mo of a paraspinal tumor, we’ve been committed to supporting pediatric cancer research. We’re honored this year's Cattle Baron’s Ball will establish Ceci’s Fund through the American Cancer Society. Please share/donate💕 cattlebaronsball.com

🧵New commentary published in JAMA Network Open on real-world treatment patterns after platinum + IO in advanced #NSCLC, work by Vamsi Velcheti, MD MBA FASCO et al.: bit.ly/4kM8uYU ◼️ Median OS: 11.2 months ◼️ Most common: Docetaxel ± ramucirumab ◼️ 131 different regimens used; IO

I had to bring this one back! #TumorBoardTuesday Kelsey Pan, MD, MPH